The success of an Aids vaccine trial that in 2009 was shown to protect 31 per cent of people studied may have been due to varying levels of antibody responses in the patients, researchers said on Thursday. Different types of antibody responses were associated with who became infected and who did not, according to an analysis of the results published in the April 5 edition of the New England Journal of Medicine.
